Sanofi's Dupixent scores double COPD win in US, China

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National Medical Products Administration (NMPA), which announced its approval the same day. It's the first ever biologic medicine for COPD in either country.